Evidence has been shown that inhibitors of VEGF and VEGFR2 reduce endothelial cell proliferation, migration and survival that lead to regression of vessel density and decrease vascular permeability, thereby slowing tumor growth [37], [38]. The gene discussed is VEGFA; the disease is neoplasm.